137 related articles for article (PubMed ID: 31127954)
1. Quality of life remains poor for patients with pemphigus vulgaris despite targeted therapies.
Schultz B; Latour E; Fett N
Br J Dermatol; 2019 Nov; 181(5):1101-1103. PubMed ID: 31127954
[No Abstract] [Full Text] [Related]
2. Rituximab therapy in pemphigus: A long-term follow-up.
Loi C; Magnano M; Ravaioli GM; Sacchelli L; Patrizi A; Bardazzi F
Dermatol Ther; 2019 Jan; 32(1):e12763. PubMed ID: 30288877
[No Abstract] [Full Text] [Related]
3. Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab.
Balighi K; Sakhi RS; Daneshpazhooh M; Mahmoudi H; Teimourpour A; Tavakolpour S
Dermatol Ther; 2018 Nov; 31(6):e12671. PubMed ID: 30246907
[No Abstract] [Full Text] [Related]
4. Evaluation of cardiac function in patients with pemphigus vulgaris before and after rituximab infusion.
Jafari M; Pighgahi M; Shahidi-Dadras M; Ghalamkarpour F; Tehranchinia Z; Abdollahimajd F; Moravvej H; Robati RM; Mozafari N; Namazi N; Diab R; Razzaghi Z; Toudeshki KK; Dadkhahfar S; Nasiri S
Arch Dermatol Res; 2024 May; 316(5):170. PubMed ID: 38734780
[No Abstract] [Full Text] [Related]
5. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.
Kushner CJ; Wang S; Tovanabutra N; Tsai DE; Werth VP; Payne AS
JAMA Dermatol; 2019 Dec; 155(12):1404-1409. PubMed ID: 31642878
[TBL] [Abstract][Full Text] [Related]
7. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months.
Balighi K; Daneshpazhooh M; Akbari Z; Tavakolpour S; Azimi P; Azizpour A
J Dermatolog Treat; 2019 Jun; 30(4):346-349. PubMed ID: 30081690
[No Abstract] [Full Text] [Related]
8. Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up.
Kim TH; Choi Y; Lee SE; Lim JM; Kim SC
J Dermatol; 2017 Jun; 44(6):615-620. PubMed ID: 28186358
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study.
Sharma VK; Bhari N; Gupta S; Sahni K; Khanna N; Ramam M; Sethuraman G
Indian J Dermatol Venereol Leprol; 2016; 82(4):389-94. PubMed ID: 27279296
[TBL] [Abstract][Full Text] [Related]
10. Pemphigus vulgaris of the epiglottis successfully treated with rituximab.
Gregoriou S; Koutsoukou XA; Panayotides I; Theodoropoulos K; Loumou P; Prikas K; Katoulis A; Rigopoulos D
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1845-6. PubMed ID: 24750415
[No Abstract] [Full Text] [Related]
11. Intralesional rituximab salvages refractory scalp lesions in a case of pemphigus vulgaris.
Gupta A; Sharma YK; Bhawalkar JS; Kothari P; Kharat R; Patil A
Dermatol Ther; 2020 Jan; 33(1):e13154. PubMed ID: 31691464
[No Abstract] [Full Text] [Related]
12. The effectiveness of rituximab in pemphigus and the benefit of additional maintenance infusions: Daily practice data from a retrospective study.
Rashid H; Lamberts A; van Maanen D; Bolling MC; Diercks GFH; Pas HH; Jonkman MF; Horváth B
J Am Acad Dermatol; 2020 Nov; 83(5):1503-1505. PubMed ID: 32540416
[No Abstract] [Full Text] [Related]
13. Sulfasalazine treatment for persistent pemphigus vulgaris oral lesions after rituximab treatment.
Navarro-Navarro I; Jiménez-Gallo D; Villegas-Romero I; Valenzuela-Ubiña S; Linares-Barrios M
Australas J Dermatol; 2021 May; 62(2):e303-e306. PubMed ID: 33200820
[No Abstract] [Full Text] [Related]
14. Comparison between the efficacy of intralesional rituximab versus intralesional triamcinolone in the treatment refractory Pemphigus Vulgaris lesions: A randomized clinical trial.
Iraji F; Danesh F; Faghihi G; Siadat A; Mokhtari F; Talakoob M; Hafezi H
Int Immunopharmacol; 2019 Aug; 73():94-97. PubMed ID: 31082727
[TBL] [Abstract][Full Text] [Related]
15. Features of coexisting granulomatosis with polyangiitis in a patient with pemphigus vulgaris: a case report.
Cala CM; Sami N
Am J Otolaryngol; 2015; 36(5):704-6. PubMed ID: 25929976
[TBL] [Abstract][Full Text] [Related]
16. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of pemphigus by varicella zoster virus after anti-CD20 treatment.
Douard PA; Delaumenie S; Pittoni J; Assikar S; Matei I; Prudhomme R; Audevard D; Bédane C
Int J Dermatol; 2020 Mar; 59(3):e52-e53. PubMed ID: 31840226
[No Abstract] [Full Text] [Related]
18. Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study.
Aryanian Z; Balighi K; Daneshpazhooh M; Karamshahi E; Hatami P; Goodarzi A; Tajalli M; Vance TM
Int Immunopharmacol; 2021 Jul; 96():107755. PubMed ID: 34162136
[TBL] [Abstract][Full Text] [Related]
19. Septic shock in a refractory pemphigus vulgaris patient after rituximab therapy.
Lima RB; Manhães MB; de Souza Felix M; Gonçalves MLC
Dermatol Ther; 2021 Jan; 34(1):e14725. PubMed ID: 33377269
[No Abstract] [Full Text] [Related]
20. Rituximab as a dual therapeutic option for pemphigus and primary cutaneous B-cell lymphomas: Two case reports.
Michelerio A; Novario M; Barruscotti S; Vassallo C
Dermatol Ther; 2019 Jul; 32(4):e12948. PubMed ID: 31025498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
